Single-chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2013 Sep 20

PMID 24048248

Citations 17

Authors

Liang Huang

Xiaomin Su

Howard J Federoff

Affiliations

Soon will be listed here.

Abstract

Accumulation of misfolded proteins has been implicated in a variety of neurodegenerative diseases including prion diseases, Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). In the past decade, single-chain fragment variable (scFv) -based immunotherapies have been developed to target abnormal proteins or various forms of protein aggregates including Aβ, SNCA, Htt, and PrP proteins. The scFvs are produced by fusing the variable regions of the antibody heavy and light chains, creating a much smaller protein with unaltered specificity. Because of its small size and relative ease of production, scFvs are promising diagnostic and therapeutic reagents for protein misfolded diseases. Studies have demonstrated the efficacy and safety of scFvs in preventing amyloid protein aggregation in preclinical models. Herein, we discuss recent developments of these immunotherapeutics. We review efforts of our group and others using scFv in neurodegenerative disease models. We illustrate the advantages of scFvs, including engineering to enhance misfolded conformer specificity and subcellular targeting to optimize therapeutic action.

Citing Articles

Isolation and Characterization of Antibodies Against Vascular Cell Adhesion Molecule-1 Reveals Putative Role for Ig-like Domains 2 and 3 in Cell-to-Cell Interaction.

Perera B, Wu Y, Pickett J, Panagides N, Barretto F, Fercher C Int J Mol Sci. 2025; 25(24.

PMID: 39769411 PMC: 11678699. DOI: 10.3390/ijms252413650.

Recombinant Antibody Fragments for Immunotherapy of Parkinson's Disease.

Manoutcharian K, Gevorkian G BioDrugs. 2024; 38(2):249-257.

PMID: 38280078 PMC: 10912140. DOI: 10.1007/s40259-024-00646-5.

Recombinant Antibody Fragments for Neurological Disorders: An Update.

Manoutcharian K, Gevorkian G Curr Neuropharmacol. 2023; 22(13):2157-2167.

PMID: 37646225 PMC: 11337690. DOI: 10.2174/1570159X21666230830142554.

Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention.

Mungchan P, Glab-Ampai K, Chruewkamlow N, Trakarnsanga K, Srisawat C, Nguyen K Molecules. 2022; 27(23).

PMID: 36500236 PMC: 9739478. DOI: 10.3390/molecules27238144.

AAV-mediated neuronal expression of an scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models.

Selles M, Fortuna J, Cercato M, Santos L, Domett L, Bitencourt A Mol Ther. 2022; 31(2):409-419.

PMID: 36369741 PMC: 9931599. DOI: 10.1016/j.ymthe.2022.11.002.

References

Verma R, Boleti E, George A . Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Methods. 1998; 216(1-2):165-81. DOI: 10.1016/s0022-1759(98)00077-5. View

Joshi S, Butler D, Messer A . Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs. 2012; 4(6):686-93. PMC: 3502235. DOI: 10.4161/mabs.21696. View

Robert R, Dolezal O, Waddington L, Hattarki M, Cappai R, Masters C . Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel. 2008; 22(3):199-208. DOI: 10.1093/protein/gzn052. View

Wei X, Roettger Y, Tan B, He Y, Dodel R, Hampel H . Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. J Biol Chem. 2012; 287(16):12858-66. PMC: 3339962. DOI: 10.1074/jbc.M111.255836. View

Polymenidou M, Moos R, Scott M, Sigurdson C, Shi Y, Yajima B . The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One. 2008; 3(12):e3872. PMC: 2592702. DOI: 10.1371/journal.pone.0003872. View

Lashuel H, Overk C, Oueslati A, Masliah E . The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2012; 14(1):38-48. PMC: 4295774. DOI: 10.1038/nrn3406. View

Peretz D, Williamson R, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G . Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature. 2001; 412(6848):739-43. DOI: 10.1038/35089090. View

La Spada A, Taylor J . Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet. 2010; 11(4):247-58. PMC: 4704680. DOI: 10.1038/nrg2748. View

Boado R, Lu J, Hui E, Pardridge W . IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol Bioeng. 2009; 105(3):627-35. PMC: 2838425. DOI: 10.1002/bit.22576. View

10.

Filesi I, Cardinale A, Mattei S, Biocca S . Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation. J Neurochem. 2007; 101(6):1516-26. DOI: 10.1111/j.1471-4159.2006.04439.x. View

11.

Zuber C, Knackmuss S, Rey C, Reusch U, Rottgen P, Frohlich T . Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol. 2007; 45(1):144-51. DOI: 10.1016/j.molimm.2007.04.030. View

12.

Hoffner G, Soues S, Djian P . Aggregation of expanded huntingtin in the brains of patients with Huntington disease. Prion. 2009; 1(1):26-31. PMC: 2633704. DOI: 10.4161/pri.1.1.4056. View

13.

Skrlj N, Drevensek G, Hudoklin S, Romih R, Serbec V, Dolinar M . Recombinant single-chain antibody with the Trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier. Appl Biochem Biotechnol. 2012; 169(1):159-69. DOI: 10.1007/s12010-012-9962-7. View

14.

Hudson P, Kortt A . High avidity scFv multimers; diabodies and triabodies. J Immunol Methods. 2000; 231(1-2):177-89. DOI: 10.1016/s0022-1759(99)00157-x. View

15.

Khoshnan A, Ko J, Patterson P . Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci U S A. 2002; 99(2):1002-7. PMC: 117420. DOI: 10.1073/pnas.022631799. View

16.

Dickson D . Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012; 2(8). PMC: 3405828. DOI: 10.1101/cshperspect.a009258. View

17.

Gao H, Hong J . Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol. 2011; 94(1):1-19. PMC: 3098527. DOI: 10.1016/j.pneurobio.2011.03.005. View

18.

Emadi S, Liu R, Yuan B, Schulz P, McAllister C, Lyubchenko Y . Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry. 2004; 43(10):2871-8. DOI: 10.1021/bi036281f. View

19.

Miller T, Zhou C, Gines S, MacDonald M, Mazarakis N, Bates G . A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol Dis. 2005; 19(1-2):47-56. DOI: 10.1016/j.nbd.2004.11.003. View

20.

Campana V, Zentilin L, Mirabile I, Kranjc A, Casanova P, Giacca M . Development of antibody fragments for immunotherapy of prion diseases. Biochem J. 2008; 418(3):507-15. DOI: 10.1042/BJ20081541. View